La catena delle opzioni mostra i dati chiave delle opzioni azionarie di CG Oncology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per CG Oncology..

CG Oncology (NASDAQ:CGON) Azioni, Catena delle Opzioni

CG Oncology

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology Inc

Keybanc analyst Sangita Jain maintains Tetra Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NASDAQ">TTEK</a>) with a Overweight and lowers the price target from $56 to $49.

News

Price Target

Analyst Ratings

TTEK

Keybanc Maintains Overweight on Tetra Tech, Lowers Price Target to $49

Morgan Stanley analyst Stephen Biggar maintains Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) with a Equal-Weight and lowers the price target from $8 to $7.

SHLS

Morgan Stanley Maintains Equal-Weight on Shoals Technologies Gr, Lowers Price Target to $7

Keybanc analyst Brett Andress maintains OneWater Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) with a Overweight and lowers the price target from $29 to $27.

ONEW

Keybanc Maintains Overweight on OneWater Marine, Lowers Price Target to $27

TKLF

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Morgan Stanley analyst Andrew Percoco maintains Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) with a Equal-Weight and lowers the price target from $12 to $6.

NOVA

Morgan Stanley Maintains Equal-Weight on Sunnova Energy Intl, Lowers Price Target to $6

American Battery Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>) reported quarterly losses of $(0.17) per share. This is a 10.53 percent increase over losses of $(0.19) per share from the same period last year. The company reported $201.96 thousand in sales this quarter.

Earnings

ABAT

American Battery Tech Q1 EPS $(0.17) Up From $(0.19) YoY, Sales $201.96K

Morgan Stanley analyst Andrew Percoco maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Equal-Weight and lowers the price target from $93 to $74.

ENPH

Morgan Stanley Maintains Equal-Weight on Enphase Energy, Lowers Price Target to $74

JMP Securities analyst Brian McKenna maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Market Outperform and raises the price target from $25 to $27.

JMP Securities Maintains Market Outperform on Blue Owl Cap, Raises Price Target to $27

WIIM

Flexible Solutions shares are trading higher. The company reported Q3 financial results.

SLGL

Sol-Gel Technologies shares are trading higher after the company reported better-than-expected Q3 financial results.

JMP Securities analyst Aaron Hecht maintains Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) with a Market Outperform and lowers the price target from $140 to $130.

JMP Securities Maintains Market Outperform on Alexandria Real Estate, Lowers Price Target to $130

Morgan Stanley analyst Stephen Byrd maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Overweight and lowers the price target from $35 to $27.

Morgan Stanley Maintains Overweight on Sunrun, Lowers Price Target to $27

Progressive shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

Morgan Stanley analyst Andrew Percoco maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Overweight and raises the price target from $301 to $367.

Morgan Stanley Maintains Overweight on GE Vernova, Raises Price Target to $367

CERO

CERo Therapeutics shares are trading higher after the company received FDA clearance for its investigational new drug application to initiate a Phase 1 clinical trial of CER-1236 for acute myelogenous leukemia.

Cantor Fitzgerald analyst Andres Sheppard maintains Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a Overweight and raises the price target from $10 to $15.

LUNR

Cantor Fitzgerald Maintains Overweight on Intuitive Machines, Raises Price Target to $15

CERo Therapeutics, Inc. Receives FDA Clearance Of Its Investigational New Drug Application To Initiate A Phase 1 Clinical Trial Of CER-1236 For Acute Myelogenous Leukemia

Evercore ISI Group analyst Mark Lipacis maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Outperform and lowers the price target from $260 to $250.

AMAT

Evercore ISI Group Maintains Outperform on Applied Mat, Lowers Price Target to $250

TransDigm Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) short percent of float has risen 8.85% since its last report. The company recently reported that it has 889 thousand shares sold short, which is 2.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TransDigm Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TransDigm Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing TransDigm Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TransDigm Gr's peer group average for short interest as a percentage of float is 3.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About TransDigm Gr?

Dynatrace's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) short percent of float has fallen 5.26% since its last report. The company recently reported that it has 6.95 million shares sold short, which is 2.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dynatrace Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dynatrace has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dynatrace's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dynatrace's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Dynatrace's Recent Short Interest

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated price target ...

Buy Rating Affirmed for CG Oncology Amid Strong Clinical Performance and Promising Market Prospects

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associate...

Optimistic Outlook for CG Oncology as Trial Cessation Boosts Cretostimogene Prospects

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target at $86....

Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Market Opportunities

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

CG Oncology's Strategic Growth and Promising Therapeutic Developments Reinforce Buy Rating

Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target...

Promising Prospects for CG Oncology, Inc.: Buy Rating Reinforced by Positive MIBC Treatment Outcomes and Market Opportunities

CG Oncology, Inc. GAAP EPS of -$0.30

CG Oncology, Inc. ( ($CGON) ) has released its Q3 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors. CG...

CG Oncology's Financial Results and Clinical Developments

ALMS

AMGN

AZNCF

BMYMP

BPMC

CATX

CGEM

CGON

ELYM

GLAXF

HAFC

IDYA

IMCR

INCY

IOVA

JANX

KURA

MRUS

NRIX

NUVL

SIRI

SNDX

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

General

CADL

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Press Releases

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

Health Care

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

Comments

CG Oncology

CG Oncology (CGON) Opzioni

CG Oncology (NASDAQ:CGON) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO